Total Payments
$86,850
2024 Payments
$6,574
Companies
95
Transactions
1,504
Medicare Patients
14,525
Medicare Billing
$3.7M
Payment Breakdown by Category
Research$55,451 (63.8%)
Food & Beverage$28,765 (33.1%)
Education$1,538 (1.8%)
Other$1,097 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $55,451 | 3 | 63.8% |
| Food and Beverage | $28,765 | 1,470 | 33.1% |
| Education | $1,538 | 20 | 1.8% |
| Long term medical supply or device loan | $1,097 | 11 | 1.3% |
Payments by Type
Research
$55,451
3 transactions
General
$31,400
1,501 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $56,191 | 49 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,835 | 113 | $0 (2024) |
| Janssen Biotech, Inc. | $1,852 | 125 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,768 | 78 | $0 (2024) |
| PFIZER INC. | $1,737 | 84 | $0 (2024) |
| Amgen Inc. | $1,493 | 78 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,468 | 68 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,378 | 81 | $0 (2024) |
| Astellas Pharma US Inc | $1,058 | 45 | $0 (2024) |
| Incyte Corporation | $910.65 | 45 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,574 | 243 | Novartis Pharmaceuticals Corporation ($1,423) |
| 2023 | $4,411 | 200 | Janssen Biotech, Inc. ($340.20) |
| 2022 | $4,349 | 211 | AstraZeneca Pharmaceuticals LP ($383.39) |
| 2021 | $3,612 | 181 | Octapharma USA, Inc. ($242.30) |
| 2020 | $2,443 | 114 | Janssen Biotech, Inc. ($271.07) |
| 2019 | $8,047 | 203 | Celgene Corporation ($4,002) |
| 2018 | $25,768 | 194 | Celgene Corporation ($22,369) |
| 2017 | $31,647 | 158 | Celgene Corporation ($29,116) |
All Payment Transactions
1,504 individual payment records from CMS Open Payments — Page 1 of 61
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $32.19 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $29.33 | General |
| Category: Oncology | ||||||
| 12/18/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $1.38 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $16.09 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/11/2024 | TerSera Therapeutics LLC | Quzyttir (Drug) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: Acute Care | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $21.34 | General |
| Category: Oncology | ||||||
| 12/06/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: Oncology | ||||||
| 12/04/2024 | PFIZER INC. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $26.45 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $31.47 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $2.82 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 11/22/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $11.72 | General |
| Category: Oncology | ||||||
| 11/21/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $23.29 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $23.17 | General |
| 11/15/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $28.93 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $30.75 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: HEMATOLOGY | ||||||
| 11/12/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $3.49 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-5013-NHL-008 | Celgene Corporation | $29,116 | 1 |
| CC-5013-NHL-008 - A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicu | Celgene Corporation | $22,369 | 1 |
| A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) | Celgene Corporation | $3,965 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 55 | 3,265 | 90,343 | $5.3M | $1.1M |
| 2022 | 56 | 3,365 | 112,872 | $3.6M | $829,352 |
| 2021 | 57 | 3,784 | 136,968 | $4.0M | $667,502 |
| 2020 | 63 | 4,111 | 192,144 | $5.8M | $1.1M |
Total Patients
14,525
Total Services
532,327
Medicare Billing
$3.7M
Procedure Codes
231
All Medicare Procedures & Services
231 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 18 | 9,400 | $1.4M | $407,512 | 29.6% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 73 | 7,600 | $567,200 | $127,427 | 22.5% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 16 | 3,662 | $918,524 | $123,360 | 13.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 45 | 5,280 | $372,060 | $98,011 | 26.3% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 42 | 24,090 | $505,890 | $56,973 | 11.3% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 22 | 600 | $527,400 | $55,371 | 10.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 196 | 352 | $78,848 | $33,125 | 42.0% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 20 | 21 | $86,520 | $25,302 | 29.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 220 | 329 | $48,887 | $21,219 | 43.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 75 | 198 | $135,828 | $19,579 | 14.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 113 | 184 | $55,936 | $8,654 | 15.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 270 | 764 | $47,368 | $7,899 | 16.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 278 | 841 | $15,979 | $7,064 | 44.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 280 | 880 | $30,800 | $6,697 | 21.7% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 15 | 16 | $10,208 | $6,560 | 64.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 59 | 93 | $14,601 | $5,958 | 40.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 45 | 45 | $15,435 | $5,803 | 37.6% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 11 | 690 | $20,700 | $4,252 | 20.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 181 | 380 | $35,340 | $4,081 | 11.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 68 | 336 | $35,280 | $3,996 | 11.3% |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 2023 | 24 | 25,560 | $51,120 | $3,891 | 7.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 20 | 55 | $18,370 | $2,748 | 15.0% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 90 | 180 | $10,440 | $2,394 | 22.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 11 | 42 | $8,610 | $2,352 | 27.3% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 83 | 128 | $9,472 | $1,892 | 20.0% |
About Dr. Samuel Myrick, MD
Dr. Samuel Myrick, MD is a Medical Oncology healthcare provider based in Ocala, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1831180546.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Samuel Myrick, MD has received a total of $86,850 in payments from pharmaceutical and medical device companies, with $6,574 received in 2024. These payments were reported across 1,504 transactions from 95 companies. The most common payment nature is "" ($55,451).
As a Medicare-enrolled provider, Myrick has provided services to 14,525 Medicare beneficiaries, totaling 532,327 services with total Medicare billing of $3.7M. Data is available for 4 years (2020–2023), covering 231 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Internal Medicine
- Location Ocala, FL
- Active Since 11/02/2005
- Last Updated 02/27/2023
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1831180546
Products in Payments
- Revlimid (Drug) $55,466
- KISQALI (Drug) $1,454
- KEYTRUDA (Biological) $1,231
- OPDIVO (Biological) $1,089
- IMBRUVICA (Drug) $987.38
- XTANDI (Drug) $838.71
- DARZALEX (Biological) $533.55
- REBLOZYL (Biological) $530.74
- Lenvima (Drug) $529.22
- ADCETRIS (Biological) $520.03
- LYNPARZA (Drug) $510.37
- ZEJULA (Drug) $480.43
- JAKAFI (Drug) $468.52
- LIBTAYO (Biological) $459.19
- ERLEADA (Drug) $455.36
- ZEPZELCA (Drug) $426.09
- INLYTA (Drug) $368.43
- MEKINIST (Drug) $358.08
- MONJUVI (Drug) $351.12
- CYRAMZA (Drug) $325.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.